• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Dopamine transporter genotype and stimulant dose-response in youth with attention-deficit/hyperactivity disorder.注意力缺陷多动障碍青少年的多巴胺转运体基因型与兴奋剂剂量反应
J Child Adolesc Psychopharmacol. 2014 Jun;24(5):238-44. doi: 10.1089/cap.2013.0102. Epub 2014 May 9.
2
Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts.缓释右苯丙胺和混合苯丙胺盐的剂量效应及相对疗效
J Child Adolesc Psychopharmacol. 2011 Dec;21(6):581-8. doi: 10.1089/cap.2011.0018. Epub 2011 Dec 2.
3
Effect of extended-release dexmethylphenidate and mixed amphetamine salts on sleep: a double-blind, randomized, crossover study in youth with attention-deficit hyperactivity disorder.缓释右美沙芬和混合苯丙胺盐对睡眠的影响：一项针对注意力缺陷多动障碍青少年的双盲、随机、交叉研究。
CNS Drugs. 2014 Sep;28(9):825-33. doi: 10.1007/s40263-014-0181-3.
4
Dopamine transporter genotype and stimulant side effect factors in youth diagnosed with attention-deficit/hyperactivity disorder.被诊断为注意力缺陷/多动障碍的青少年的多巴胺转运体基因型与兴奋剂副作用因素
J Child Adolesc Psychopharmacol. 2009 Jun;19(3):233-9. doi: 10.1089/cap.2008.0133.
5
Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.混合安非他明盐缓释剂（阿得拉XR）治疗青少年注意缺陷多动障碍的疗效与安全性：一项为期4周的随机、双盲、安慰剂对照平行组研究。
Clin Ther. 2006 Feb;28(2):266-79. doi: 10.1016/j.clinthera.2006.02.011.
6
SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results of a Randomized, Double-Blind Placebo-Controlled Study.SHP465混合苯丙胺盐治疗儿童和青少年注意力缺陷/多动障碍：一项随机、双盲、安慰剂对照研究的结果。
J Child Adolesc Psychopharmacol. 2018 Feb;28(1):19-28. doi: 10.1089/cap.2017.0053. Epub 2017 Aug 17.
7
Dopamine transporter genotype influences the physiological response to medication in ADHD.多巴胺转运体基因分型影响多动症患者对药物的生理反应。
Brain. 2006 Aug;129(Pt 8):2038-46. doi: 10.1093/brain/awl147. Epub 2006 Jun 7.
8
Dopamine transporter genotype and methylphenidate dose response in children with ADHD.注意缺陷多动障碍儿童的多巴胺转运体基因型与哌甲酯剂量反应
Neuropsychopharmacology. 2005 Jul;30(7):1374-82. doi: 10.1038/sj.npp.1300718.
9
Dopamine-related genotypes and the dose-response effect of methylphenidate on eating in attention-deficit/hyperactivity disorder youths.多巴胺相关基因型与哌甲酯对注意力缺陷多动障碍青少年饮食的剂量反应效应。
J Child Adolesc Psychopharmacol. 2009 Apr;19(2):127-36. doi: 10.1089/cap.2008.046.
10
Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder.注意缺陷多动障碍中美托咪定剂量反应的药物遗传学预测因子。
J Am Acad Child Adolesc Psychiatry. 2011 Nov;50(11):1129-1139.e2. doi: 10.1016/j.jaac.2011.08.002. Epub 2011 Sep 15.

引用本文的文献

1
Change in striatal functional connectivity networks across 2 years due to stimulant exposure in childhood ADHD: results from the ABCD sample.由于儿童 ADHD 中兴奋剂的暴露，纹状体功能连接网络在 2 年内发生变化：来自 ABCD 样本的结果。
Transl Psychiatry. 2024 Nov 6;14(1):463. doi: 10.1038/s41398-024-03165-7.
2
Dopamine Transporter and Gene Relationships with Attention-Deficit/Hyperactivity Disorder Treatment Response in the Methylphenidate and Atomoxetine Crossover Study.在哌甲酯和托莫西汀交叉研究中多巴胺转运体及基因与注意力缺陷多动障碍治疗反应的关系
J Child Adolesc Psychopharmacol. 2024 Dec;34(10):458-469. doi: 10.1089/cap.2024.0069. Epub 2024 Oct 10.
3
Change in Striatal Functional Connectivity Networks Across Two Years Due to Stimulant Exposure in Childhood ADHD: Results from the ABCD Sample.童年多动症患者因兴奋剂暴露导致的纹状体功能连接网络在两年间的变化：青少年大脑认知发展研究（ABCD）样本的结果
medRxiv. 2024 Jun 18:2024.03.18.24304470. doi: 10.1101/2024.03.18.24304470.
4
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).哌醋甲酯治疗注意缺陷多动障碍（ADHD）儿童和青少年。
Cochrane Database Syst Rev. 2023 Mar 27;3(3):CD009885. doi: 10.1002/14651858.CD009885.pub3.
5
CES1 and SLC6A2 Genetic Variants As Predictors of Response To Methylphenidate in Autism Spectrum Disorders.CES1和SLC6A2基因变异作为自闭症谱系障碍中对哌醋甲酯反应的预测指标
Pharmgenomics Pers Med. 2022 Nov 8;15:951-957. doi: 10.2147/PGPM.S377210. eCollection 2022.
6
Genetic Influence on Efficacy of Pharmacotherapy for Pediatric Attention-Deficit/Hyperactivity Disorder: Overview and Current Status of Research.遗传因素对儿童注意力缺陷/多动障碍药物治疗疗效的影响：研究概述与现状
CNS Drugs. 2020 Apr;34(4):389-414. doi: 10.1007/s40263-020-00702-y.
7
PharmGKB summary: methylphenidate pathway, pharmacokinetics/pharmacodynamics.药物基因组学知识库总结：哌甲酯途径，药代动力学/药效学。
Pharmacogenet Genomics. 2019 Aug;29(6):136-154. doi: 10.1097/FPC.0000000000000376.
8
Specific Genes Associated with Adverse Events of Methylphenidate Use in the Pediatric Population: A Systematic Literature Review.与儿科人群使用哌甲酯不良事件相关的特定基因：一项系统文献综述
J Res Pharm Pract. 2017 Apr-Jun;6(2):65-72. doi: 10.4103/jrpp.JRPP_16_161.
9
Developmental stress elicits preference for methamphetamine in the spontaneously hypertensive rat model of attention-deficit/hyperactivity disorder.在注意力缺陷多动障碍的自发性高血压大鼠模型中，发育应激引发对甲基苯丙胺的偏好。
Behav Brain Funct. 2016 Jun 17;12(1):18. doi: 10.1186/s12993-016-0102-3.
10
Premature responding is associated with approach to a food cue in male and female heterogeneous stock rats.在雄性和雌性异质品系大鼠中，过早反应与对食物线索的趋近有关。
Psychopharmacology (Berl). 2016 Jul;233(13):2593-605. doi: 10.1007/s00213-016-4306-x. Epub 2016 May 5.

本文引用的文献

1
Meta-analysis of the association between dopamine transporter genotype and response to methylphenidate treatment in ADHD.注意缺陷多动障碍中多巴胺转运体基因型与哌甲酯治疗反应之间关联的荟萃分析。
Pharmacogenomics J. 2014 Feb;14(1):77-84. doi: 10.1038/tpj.2013.9. Epub 2013 Apr 16.
2
Candidate gene studies of a promising intermediate phenotype: failure to replicate.候选基因研究的一个有前途的中间表型：未能复制。
Neuropsychopharmacology. 2013 Apr;38(5):802-16. doi: 10.1038/npp.2012.245. Epub 2012 Dec 3.
3
Functional genomics of attention-deficit/hyperactivity disorder (ADHD) risk alleles on dopamine transporter binding in ADHD and healthy control subjects.注意缺陷多动障碍（ADHD）风险等位基因对多巴胺转运体结合的功能基因组学研究：ADHD 患者和健康对照者。
Biol Psychiatry. 2013 Jul 15;74(2):84-9. doi: 10.1016/j.biopsych.2012.11.010. Epub 2012 Dec 27.
4
Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts.缓释右苯丙胺和混合苯丙胺盐的剂量效应及相对疗效
J Child Adolesc Psychopharmacol. 2011 Dec;21(6):581-8. doi: 10.1089/cap.2011.0018. Epub 2011 Dec 2.
5
Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder.注意缺陷多动障碍中美托咪定剂量反应的药物遗传学预测因子。
J Am Acad Child Adolesc Psychiatry. 2011 Nov;50(11):1129-1139.e2. doi: 10.1016/j.jaac.2011.08.002. Epub 2011 Sep 15.
6
Mapping genes that predict treatment outcome in admixed populations.在混合人群中定位预测治疗效果的基因。
Pharmacogenomics J. 2010 Dec;10(6):465-77. doi: 10.1038/tpj.2010.71. Epub 2010 Oct 5.
7
Dose-response characteristics in adolescents with attention-deficit/hyperactivity disorder treated with OROS methylphenidate in a 4-week, open-label, dose-titration study.在一项为期4周的开放标签剂量滴定研究中，使用OROS哌甲酯治疗的注意力缺陷/多动障碍青少年的剂量反应特征。
J Child Adolesc Psychopharmacol. 2010 Jun;20(3):187-96. doi: 10.1089/cap.2009.0102.
8
Using Meta-analysis to Compare the Efficacy of Medications for Attention-Deficit/Hyperactivity Disorder in Youths.使用荟萃分析比较青少年注意力缺陷多动障碍药物的疗效。
P T. 2009 Dec;34(12):678-94.
9
Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics.注意缺陷多动障碍药物遗传学的进展与前景。
CNS Drugs. 2010 Feb;24(2):99-117. doi: 10.2165/11530290-000000000-00000.
10
Adverse reactions to methylphenidate treatment for attention-deficit/hyperactivity disorder: structure and associations with clinical characteristics and symptom control.用于治疗注意力缺陷/多动障碍的哌甲酯的不良反应：结构及其与临床特征和症状控制的关联
J Child Adolesc Psychopharmacol. 2009 Dec;19(6):683-90. doi: 10.1089/cap.2009.0024.

注意力缺陷多动障碍青少年的多巴胺转运体基因型与兴奋剂剂量反应

Dopamine transporter genotype and stimulant dose-response in youth with attention-deficit/hyperactivity disorder.

作者信息

Stein Mark A, Waldman Irwin, Newcorn Jeffrey, Bishop Jeffrey, Kittles Rick, Cook Edwin H

机构信息

1 Department of Psychiatry and Behavioral Medicine, Seattle Children's Hospital, and University of Washington , Seattle, Washington.

出版信息

J Child Adolesc Psychopharmacol. 2014 Jun;24(5):238-44. doi: 10.1089/cap.2013.0102. Epub 2014 May 9.

DOI:10.1089/cap.2013.0102
PMID:24813374
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4064733/
Abstract

OBJECTIVES

This study seeks to determine if variation in the dopamine transporter gene (SLC6A3/DAT1) moderates the dose-response effects of long-acting dexmethylphenidate (D-MPH) and mixed amphetamine salts (MAS) in children with attention-deficit/hyperactivity disorder (ADHD).

METHODS

Fifty-six children and adolescents (mean age=11.7±2.2) participated in a double-blind, two period crossover, dose-response study with a randomized placebo week in each 4 week drug period. Each period consisted of sequential week-long exposures to three dose levels (10, 20, 25-30 mg, depending upon weight) of D-MPH or MAS.

RESULTS

Doses of 10-20 mg of either D-MPH or MAS had little to no effect on hyperactivity-impulsivity and total ADHD symptom scores in subjects with the 9/9 genotype; this was in contrast to the dose-response curves of subjects with either the 10/10 or 10/9 genotype.

CONCLUSIONS

ADHD youth with the 9/9 genotype may require higher stimulant doses to achieve adequate symptom control.

摘要

目的

本研究旨在确定多巴胺转运体基因（SLC6A3/DAT1）的变异是否会调节长效右苯丙胺（D-MPH）和苯丙胺混合盐（MAS）对注意力缺陷多动障碍（ADHD）儿童的剂量反应效应。

方法

56名儿童和青少年（平均年龄 = 11.7±2.2）参与了一项双盲、两阶段交叉的剂量反应研究，在每个为期4周的药物治疗阶段都有一个随机的安慰剂周。每个阶段包括连续一周接触三种剂量水平（根据体重分别为10、20、25 - 30毫克）的D-MPH或MAS。

结果

对于9/9基因型的受试者，10 - 20毫克的D-MPH或MAS剂量对多动冲动及ADHD总症状评分几乎没有影响；这与10/10或10/9基因型受试者的剂量反应曲线形成对比。

结论

9/9基因型的ADHD青少年可能需要更高剂量的兴奋剂才能实现足够的症状控制。